Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Maxhealth to Distribute Legacy's Hair Loss Treatment in China

publication date: Oct 27, 2017

Maxhealth Medicine of Wuxi, China struck a deal with Switzerland's Legacy Healthcare to commercialize Legacy's CG 210 in Mainland China and Macao. CG210 is a botanical treatment for hair loss that has been shown to slow the rate of hair loss. Legacy develops innovative patentable botanical drugs in oncology supportive care and dermatology. Maxhealth, which commercializes drugs and medical devices in China, made an investment in Legacy, though financial details were not disclosed. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital